Actuate Therapeutics (ACTU) Non-Current Assets (2024 - 2025)
Actuate Therapeutics (ACTU) posted quarterly Non-Current Assets of $392491.0 for Q4 2025, up 255.04% year-over-year from $110548.0 in Q4 2024, and up 45.4% quarter-over-quarter from $269934.0 in Q3 2025.
Actuate Therapeutics (ACTU) Non-Current Assets (2024 - 2025) Analysis & Trends
Actuate Therapeutics (ACTU) has reported Non-Current Assets for 2 consecutive years, with $392491.0 the latest figure, recorded in Q4 2025.
- In Q4 2025, Non-Current Assets rose 255.04% year-over-year to $392491.0; the TTM figure through Dec 2025 stood at $1.2 million (down 8.86% YoY), while the FY2025 annual figure was $392491.0, up 255.04% from the prior year.
- Non-Current Assets advanced to $392491.0 in Q4 2025 per ACTU's latest filing, from $269934.0 in the prior quarter.
- Across five years, Non-Current Assets topped out at $1.2 million in Q2 2024 and bottomed at $110548.0 in Q4 2024.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 14.88 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 23.28 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 1.96 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 5.15 Bn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 1.96 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 938.60 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 6.80 Bn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 468.65 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 18.06 Bn |
| 10 | Actuate Therapeutics | 30.08 Mn | 30.08 Mn | - | 451,398.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 392,491.00 |
| Sep 30, 2025 | 269,934.00 |
| Jun 30, 2025 | 280,342.00 |
| Mar 31, 2025 | 234,475.00 |
| Dec 31, 2024 | 110,548.00 |
| Jun 30, 2024 | 1.18 Mn |